A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors andKRASmutant colorectal cancer
Deming, Dustin A., Cavalcante, Ludmila L., Lubner, Sam J., Mulkerin, Daniel L., LoConte, Noelle K., Eickhoff, Jens C., Kolesar, Jill M., Fioravanti, Suzanne, Greten, Tim F., Compton, Kathryn, Doyle, AVolume:
34
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-015-0314-7
Date:
April, 2016
File:
PDF, 300 KB
english, 2016